MediWound Ltd. Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2022. The filing is an annual Form 20-F, not a quarterly filing; the source text does not provide standalone 2022 fourth-quarter results. Financial statements are prepared under IFRS as issued by the IASB and reported in U.S. dollars.
Business Context
MediWound is an Israeli biopharmaceutical company developing, manufacturing and commercializing enzymatic therapies for burn care, wound care and tissue repair. Its commercial product is NexoBrid, a bromelain-based product for non-surgical eschar removal in adults with deep partial- and full-thickness thermal burns. EscharEx is in clinical development for chronic and hard-to-heal wounds, and MW005 is in Phase I/II development for low-risk basal cell carcinoma.
- NexoBrid received U.S. FDA authorization in December 2022, triggering a $7.5 million milestone payment from Vericel.
- NexoBrid also received marketing authorization in Japan and India in December 2022.
- EscharEx Phase II studies produced positive debridement results; the company expected to initiate a pivotal Phase III study in the second half of 2023.
- MW005 produced positive preliminary Phase I/II results; final results were expected in the third quarter of 2023.
- The company manufactures its products at a single cGMP-certified facility in Yavne, Israel.
Financial Performance and Position
| U.S. dollars in thousands, except per-share data | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $26,496 | $23,763 | +11.5% |
| Gross profit | $13,165 | $8,771 | +50.1% |
| Gross margin | 49.7% | 36.9% | +12.8 percentage points |
| Operating loss | $(8,345) | $(11,221) | Improved by $2,876 |
| Net loss | $(19,599) | $(13,551) | Worsened by $6,048 |
| Basic and diluted loss per share | $(3.93) | $(3.48) | Worsened |
| Net cash used in operating activities | $(11,885) | $(8,916) | Higher cash use |
| Capital expenditures | $555 | $489 | Higher |
- Product revenue declined 44% to $5.3 million, primarily because BARDA emergency stockpile procurement decreased by $4.3 million.
- Development-services revenue increased 5% to $12.9 million.
- License revenue increased to $8.2 million from $1.8 million, primarily due to the $7.5 million Vericel FDA-approval milestone.
- BARDA represented 51% of total revenue, compared with 76% in 2021; Vericel represented 28% of 2022 revenue.
- Cost of revenue decreased to $13.3 million from $15.0 million, reducing cost of revenue as a percentage of revenue from 63% to 50%.
- Research and development expense was $10.2 million, substantially unchanged from 2021. Selling and marketing expense increased 10% to $3.7 million, while general and administrative expense increased 9% to $6.9 million.
- Net financial expense increased to $11.2 million from $2.3 million, primarily because of $8.98 million of warrant revaluation expense and $1.91 million of warrant issuance expenses.
- Cash and cash equivalents were $33.9 million at year-end, compared with $11.0 million at December 31, 2021. Total current assets were $45.8 million versus current liabilities of $12.1 million.
- The company reported no long-term debt exposure in its market-risk discussion, although it had $2.24 million of current maturities of long-term liabilities, lease liabilities, IIA grant liabilities, and other commitments.
- Total assets were $50.0 million, total liabilities were $39.1 million, and shareholders’ equity was $10.9 million at December 31, 2022.
- The filing reports an accumulated deficit of $168.1 million in the consolidated financial statements. One MD&A passage instead states $157 million; the filing text does not clearly reconcile this discrepancy.
Material Changes Versus 2021
- Revenue increased despite lower product sales, reflecting the Vericel approval milestone and higher development-services revenue.
- Gross margin improved materially because of the revenue mix and lower overall cost of revenues.
- Operating loss narrowed, but net loss increased because of warrant-related financial expenses.
- Operating cash use increased by $3.0 million, while financing activities provided $35.8 million compared with $1.1 million of cash used in 2021.
- The company raised approximately $41.7 million gross in March, September and October 2022 offerings. The financings included ordinary shares, pre-funded warrants and warrants, creating potential future dilution.
- A 1-for-7 reverse share split became effective December 20, 2022. Historical share and per-share information was retrospectively adjusted.
- The company initiated a manufacturing facility scale-up expected to cost approximately $10 million to $12 million.
- Management changes occurred during 2022, including the appointment of a new CEO and COO; related one-time expenses contributed to higher general and administrative and other expenses.
Liquidity, Outlook and Contingencies
Management stated that existing cash, cash equivalents and short-term bank deposits were expected to fund operating expenses and capital requirements into 2026, and elsewhere stated that liquidity was sufficient for at least the next 24 months. The company nevertheless expects continued operating losses and may need additional capital depending on revenue growth, milestone timing, research and development spending, manufacturing expansion and international commercialization.
- BARDA contracts have an aggregate potential value described in the filing of approximately $200 million to $209 million, including development funding and procurement options. BARDA may terminate either contract for convenience, and future options may not be exercised.
- As of December 31, 2022, the company had received approximately $82.2 million of BARDA development funding and an additional $16.5 million for NexoBrid procurement, subject to a profit-sharing arrangement with Vericel.
- Vericel may owe up to $125 million in future sales milestones and tiered royalties on North American NexoBrid sales, but commercialization depends on Vericel’s execution and market acceptance.
- The company relies on a single supplier, Challenge Bioproducts Corporation, for bromelain SP, a key starting material. Management estimated that stored inventory supported approximately two years of full-capacity operations, but disruption could delay manufacturing and clinical programs.
- The company is dependent on a single manufacturing facility in Israel and faces risks from war, terrorism, equipment failure, contamination, regulatory inspections and capacity-expansion execution.
- Patent protection for NexoBrid is nominally scheduled to expire in various jurisdictions beginning in 2025, absent extensions; EscharEx-related patents are expected to expire in 2037 absent adjustments or extensions.
- The company has continuing obligations to the Israeli Innovation Authority. The IIA liability was $7.6 million at December 31, 2022, while total grants received, including accrued interest and net of royalties, were approximately $13.6 million.
- The company remains obligated to make payments under its Teva settlement; recorded liabilities totaled approximately $4.8 million at year-end, and additional contingent indemnity exposure of up to $10.2 million was disclosed for certain claims notified before December 31, 2023.
- After year-end, the company completed a February 2023 offering generating $27.5 million gross proceeds through the issuance of 1,964,286 ordinary shares.
Principal Risks and Unusual Items
- Regulatory approval, post-marketing obligations and clinical-development uncertainty could delay or prevent commercialization of EscharEx, MW005 or expanded NexoBrid indications.
- Revenue concentration is substantial: BARDA and Vericel together contributed approximately 79% of 2022 revenue.
- Market acceptance, pricing, reimbursement, competition from surgery and existing wound-care therapies, and the ability to establish NexoBrid as a standard of care remain uncertain.
- Warrant accounting produced significant non-cash and issuance-related expenses in 2022, materially increasing the net loss.
- Foreign-exchange exposure is significant because approximately 47% of 2022 operating expenses were denominated in Israeli shekels, with additional euro exposure. Management estimated that a 10% change in the NIS and euro against the U.S. dollar would affect annual net profit or loss by approximately $1.65 million.
- Inflation, interest rates, recessionary conditions, supply-chain disruption, geopolitical conflict involving Israel or Taiwan, cybersecurity incidents and changing healthcare-pricing regulations could adversely affect results.
- The company has never paid dividends and does not expect to do so in the foreseeable future.
Facts Investors Should Verify
- Reconcile the conflicting accumulated-deficit figures of $168.1 million and $157 million presented in different sections of the filing.
- Assess the sustainability of revenue after the one-time $7.5 million Vericel milestone and the dependence on BARDA procurement and development funding.
- Confirm the timing, cost and regulatory status of the $10 million to $12 million manufacturing scale-up.
- Review the terms, valuation and potential dilution from the outstanding warrants, options and subsequent February 2023 equity offering.
- Track Vericel’s U.S. launch and sales performance, future BARDA procurement, royalties and milestone eligibility.
- Evaluate cash burn, working-capital requirements and whether management’s projected liquidity runway remains realistic under continued operating losses.
- Verify progress of the EscharEx Phase III program, MW005 development and the pediatric NexoBrid indication.
- Review exposure to the sole bromelain SP supplier, the Yavne manufacturing facility, IIA and Teva liabilities, and disclosed contingent obligations.